A newly developed radiopharmaceutical pair can precisely detect and effectively treat gastric and pancreatic tumors, ...
ImmunityBio, Inc. is upgraded to Buy reflecting improving Anktiva data & potential label expansions in NMIBC and NSCLC. Read ...
Xtandi, Astellas’ roughly $6 billion prostate cancer juggernaut by annual sales, is set to lose U.S. patent protection in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback